HF patients were treated with CSCs enriched for ES and mesenchymal stem cell (MSC) markers in the Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy (ALCADIA) trial [66] and the injection sites were covered by a biodegradable gelatin hydrogel sheet containing 200 μm basic fibroblast growth factor (bFGF). Here, FGF2 is linked to hydrops fetalis.